Annual CFI
-$49.94 M
+$21.14 M+29.73%
December 31, 2023
Summary
- As of February 7, 2025, LXRX annual cash flow from investing activities is -$49.94 million, with the most recent change of +$21.14 million (+29.73%) on December 31, 2023.
- During the last 3 years, LXRX annual CFI has fallen by -$430.70 million (-113.12%).
- LXRX annual CFI is now -113.12% below its all-time high of $380.76 million, reached on December 31, 2020.
Performance
LXRX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$53.47 M
+$65.79 M+533.90%
September 30, 2024
Summary
- As of February 7, 2025, LXRX quarterly cash flow from investing activities is $53.47 million, with the most recent change of +$65.79 million (+533.90%) on September 30, 2024.
- Over the past year, LXRX quarterly CFI has increased by +$163.69 million (+148.51%).
- LXRX quarterly CFI is now -75.22% below its all-time high of $215.80 million, reached on September 30, 2020.
Performance
LXRX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$17.18 M
+$92.80 M+84.38%
September 30, 2024
Summary
- As of February 7, 2025, LXRX TTM cash flow from investing activities is -$17.18 million, with the most recent change of +$92.80 million (+84.38%) on September 30, 2024.
- Over the past year, LXRX TTM CFI has increased by +$155.08 million (+90.03%).
- LXRX TTM CFI is now -104.51% below its all-time high of $380.76 million, reached on December 31, 2020.
Performance
LXRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
LXRX Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.7% | +148.5% | +90.0% |
| 3 y3 years | -113.1% | +169.3% | +80.7% |
| 5 y5 years | -129.4% | +270.9% | +89.0% |
LXRX Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2467.0% | +29.7% | at high | +148.5% | -211.4% | +90.0% |
| 5 y | 5-year | -113.1% | +68.0% | -75.2% | +148.5% | -104.5% | +90.0% |
| alltime | all time | -113.1% | +73.4% | -75.2% | +131.3% | -104.5% | +92.2% |
Lexicon Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $53.47 M(-533.9%) | -$17.18 M(-84.4%) |
| Jun 2024 | - | -$12.32 M(-88.8%) | -$109.97 M(-36.2%) |
| Mar 2024 | - | -$110.22 M(-312.4%) | -$172.26 M(+244.9%) |
| Dec 2023 | -$49.94 M(-29.7%) | $51.90 M(-232.0%) | -$49.94 M(-35.7%) |
| Sep 2023 | - | -$39.33 M(-47.3%) | -$77.67 M(-32.8%) |
| Jun 2023 | - | -$74.61 M(-717.0%) | -$115.54 M(+111.7%) |
| Mar 2023 | - | $12.09 M(-50.0%) | -$54.58 M(-23.2%) |
| Dec 2022 | -$71.08 M(-3468.6%) | $24.17 M(-131.3%) | -$71.08 M(-20.3%) |
| Sep 2022 | - | -$77.20 M(+465.6%) | -$89.16 M(+621.3%) |
| Jun 2022 | - | -$13.65 M(+209.6%) | -$12.36 M(-180.1%) |
| Mar 2022 | - | -$4.41 M(-172.3%) | $15.43 M(+631.1%) |
| Dec 2021 | $2.11 M(-99.4%) | $6.10 M(-1624.0%) | $2.11 M(-94.7%) |
| Sep 2021 | - | -$400.00 K(-102.8%) | $40.12 M(-84.3%) |
| Jun 2021 | - | $14.14 M(-179.8%) | $256.32 M(-20.0%) |
| Mar 2021 | - | -$17.72 M(-140.2%) | $320.25 M(-15.9%) |
| Dec 2020 | $380.76 M(-344.3%) | $44.10 M(-79.6%) | $380.76 M(+67.5%) |
| Sep 2020 | - | $215.80 M(+176.4%) | $227.26 M(-1246.2%) |
| Jun 2020 | - | $78.07 M(+82.5%) | -$19.83 M(-81.2%) |
| Mar 2020 | - | $42.78 M(-139.1%) | -$105.35 M(-32.4%) |
| Dec 2019 | -$155.85 M(-191.9%) | -$109.40 M(+249.7%) | -$155.85 M(-1367.7%) |
| Sep 2019 | - | -$31.28 M(+319.9%) | $12.29 M(-87.7%) |
| Jun 2019 | - | -$7.45 M(-3.6%) | $99.97 M(-35.4%) |
| Mar 2019 | - | -$7.73 M(-113.2%) | $154.79 M(-8.7%) |
| Dec 2018 | $169.58 M(+235.6%) | $58.75 M(+4.2%) | $169.58 M(-779.9%) |
| Sep 2018 | - | $56.40 M(+19.1%) | -$24.94 M(-536.7%) |
| Jun 2018 | - | $47.37 M(+570.6%) | $5.71 M(-62.3%) |
| Mar 2018 | - | $7.06 M(-105.2%) | $15.13 M(-70.1%) |
| Dec 2017 | $50.52 M(+176.8%) | -$135.77 M(-256.0%) | $50.52 M(-79.2%) |
| Sep 2017 | - | $87.05 M(+53.3%) | $242.75 M(+28.0%) |
| Jun 2017 | - | $56.79 M(+33.8%) | $189.60 M(-2.4%) |
| Mar 2017 | - | $42.45 M(-24.8%) | $194.35 M(+964.8%) |
| Dec 2016 | $18.25 M(-115.6%) | $56.46 M(+66.6%) | $18.25 M(-111.2%) |
| Sep 2016 | - | $33.90 M(-44.9%) | -$162.34 M(+37.0%) |
| Jun 2016 | - | $61.54 M(-146.0%) | -$118.47 M(-34.1%) |
| Mar 2016 | - | -$133.64 M(+7.7%) | -$179.67 M(+53.5%) |
| Dec 2015 | -$117.02 M(+7.9%) | -$124.14 M(-259.6%) | -$117.02 M(-28.5%) |
| Sep 2015 | - | $77.77 M(>+9900.0%) | -$163.60 M(-25.9%) |
| Jun 2015 | - | $340.00 K(-100.5%) | -$220.86 M(+0.4%) |
| Mar 2015 | - | -$70.99 M(-58.4%) | -$219.98 M(+102.9%) |
| Dec 2014 | -$108.42 M(-208.9%) | -$170.72 M(-932.5%) | -$108.42 M(-206.2%) |
| Sep 2014 | - | $20.51 M(+1576.7%) | $102.07 M(+0.3%) |
| Jun 2014 | - | $1.22 M(-97.0%) | $101.80 M(-8.3%) |
| Mar 2014 | - | $40.57 M(+2.0%) | $111.00 M(+11.5%) |
| Dec 2013 | $99.54 M(-201.8%) | $39.77 M(+96.5%) | $99.54 M(+87.7%) |
| Sep 2013 | - | $20.24 M(+94.1%) | $53.04 M(+19.3%) |
| Jun 2013 | - | $10.43 M(-64.2%) | $44.45 M(-27.0%) |
| Mar 2013 | - | $29.11 M(-532.6%) | $60.88 M(-162.2%) |
| Dec 2012 | -$97.81 M | -$6.73 M(-157.8%) | -$97.81 M(+33.9%) |
| Sep 2012 | - | $11.64 M(-56.6%) | -$73.05 M(+35.4%) |
| Jun 2012 | - | $26.86 M(-120.7%) | -$53.95 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$129.57 M(-818.6%) | -$54.30 M(-177.6%) |
| Dec 2011 | $69.95 M(-161.4%) | $18.03 M(-41.3%) | $69.95 M(-175.1%) |
| Sep 2011 | - | $30.74 M(+16.0%) | -$93.18 M(-25.3%) |
| Jun 2011 | - | $26.50 M(-598.3%) | -$124.73 M(+2.9%) |
| Mar 2011 | - | -$5.32 M(-96.3%) | -$121.26 M(+6.5%) |
| Dec 2010 | -$113.84 M(-1058.5%) | -$145.10 M(>+9900.0%) | -$113.84 M(-457.9%) |
| Sep 2010 | - | -$810.00 K(-102.7%) | $31.80 M(-51.1%) |
| Jun 2010 | - | $29.97 M(+1327.7%) | $65.05 M(-6.0%) |
| Mar 2010 | - | $2.10 M(+283.0%) | $69.17 M(+482.4%) |
| Dec 2009 | $11.88 M(-92.5%) | $548.00 K(-98.3%) | $11.88 M(-29.8%) |
| Sep 2009 | - | $32.44 M(-4.9%) | $16.91 M(-930.7%) |
| Jun 2009 | - | $34.09 M(-161.8%) | -$2.04 M(-105.0%) |
| Mar 2009 | - | -$55.20 M(-1088.3%) | $40.93 M(-74.3%) |
| Dec 2008 | $159.41 M(-184.8%) | $5.58 M(-58.6%) | $159.41 M(+13.3%) |
| Sep 2008 | - | $13.48 M(-82.5%) | $140.74 M(-691.3%) |
| Jun 2008 | - | $77.05 M(+21.7%) | -$23.80 M(-82.3%) |
| Mar 2008 | - | $63.29 M(-583.6%) | -$134.21 M(-28.6%) |
| Dec 2007 | -$187.95 M(-868.2%) | -$13.09 M(-91.3%) | -$187.95 M(+2.1%) |
| Sep 2007 | - | -$151.06 M(+352.9%) | -$184.16 M(+667.3%) |
| Jun 2007 | - | -$33.36 M(-449.1%) | -$24.00 M(-206.1%) |
| Mar 2007 | - | $9.55 M(-202.8%) | $22.61 M(-7.6%) |
| Dec 2006 | $24.46 M(-253.0%) | -$9.30 M(-202.2%) | $24.46 M(+15.0%) |
| Sep 2006 | - | $9.10 M(-31.4%) | $21.27 M(+674.0%) |
| Jun 2006 | - | $13.26 M(+16.2%) | $2.75 M(-116.6%) |
| Mar 2006 | - | $11.41 M(-191.3%) | -$16.52 M(+3.3%) |
| Dec 2005 | -$15.99 M(-139.5%) | -$12.49 M(+32.5%) | -$15.99 M(-685.5%) |
| Sep 2005 | - | -$9.43 M(+56.9%) | $2.73 M(-82.4%) |
| Jun 2005 | - | -$6.01 M(-150.3%) | $15.52 M(-77.5%) |
| Mar 2005 | - | $11.93 M(+91.6%) | $68.85 M(+70.1%) |
| Dec 2004 | $40.48 M(<-9900.0%) | $6.23 M(+85.2%) | $40.48 M(+73.3%) |
| Sep 2004 | - | $3.36 M(-92.9%) | $23.36 M(+115.3%) |
| Jun 2004 | - | $47.33 M(-387.9%) | $10.85 M(-134.8%) |
| Mar 2004 | - | -$16.44 M(+51.0%) | -$31.20 M(>+9900.0%) |
| Dec 2003 | -$128.00 K(-100.3%) | -$10.89 M(+19.0%) | -$128.00 K(-99.6%) |
| Sep 2003 | - | -$9.15 M(-273.5%) | -$30.21 M(-300.8%) |
| Jun 2003 | - | $5.27 M(-64.0%) | $15.05 M(-47.0%) |
| Mar 2003 | - | $14.63 M(-135.7%) | $28.40 M(-39.9%) |
| Dec 2002 | $47.23 M(+247.1%) | -$40.97 M(-213.5%) | $47.23 M(-52.2%) |
| Sep 2002 | - | $36.11 M(+93.8%) | $98.70 M(+117.2%) |
| Jun 2002 | - | $18.63 M(-44.3%) | $45.44 M(-2010.7%) |
| Mar 2002 | - | $33.46 M(+218.3%) | -$2.38 M(-117.5%) |
| Dec 2001 | $13.60 M(-107.6%) | $10.51 M(-161.3%) | $13.60 M(+327.4%) |
| Sep 2001 | - | -$17.15 M(-41.2%) | $3.18 M(-182.7%) |
| Jun 2001 | - | -$29.19 M(-159.0%) | -$3.85 M(-97.0%) |
| Mar 2001 | - | $49.44 M(>+9900.0%) | -$129.64 M(-27.7%) |
| Dec 2000 | -$179.33 M(-3548.6%) | $88.60 K(-100.4%) | -$179.33 M(-0.0%) |
| Sep 2000 | - | -$24.19 M(-84.4%) | -$179.42 M(+15.6%) |
| Jun 2000 | - | -$154.98 M(>+9900.0%) | -$155.23 M(>+9900.0%) |
| Mar 2000 | - | -$246.60 K | -$246.60 K |
| Dec 1999 | $5.20 M | - | - |
FAQ
- What is Lexicon Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual CFI year-on-year change?
- What is Lexicon Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly CFI year-on-year change?
- What is Lexicon Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals TTM CFI year-on-year change?
What is Lexicon Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of LXRX is -$49.94 M
What is the all time high annual CFI for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual cash flow from investing activities is $380.76 M
What is Lexicon Pharmaceuticals annual CFI year-on-year change?
Over the past year, LXRX annual cash flow from investing activities has changed by +$21.14 M (+29.73%)
What is Lexicon Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of LXRX is $53.47 M
What is the all time high quarterly CFI for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly cash flow from investing activities is $215.80 M
What is Lexicon Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, LXRX quarterly cash flow from investing activities has changed by +$163.69 M (+148.51%)
What is Lexicon Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of LXRX is -$17.18 M
What is the all time high TTM CFI for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high TTM cash flow from investing activities is $380.76 M
What is Lexicon Pharmaceuticals TTM CFI year-on-year change?
Over the past year, LXRX TTM cash flow from investing activities has changed by +$155.08 M (+90.03%)